The coronavirus disease 2019 (COVID-19) is a respiratory illness that has caused a global pandemic since early 2020 and led to the hospitalization and death of millions. COVID-19 has been shown to compromise the cardiovascular system, including the functions of the heart and blood vessels. Patients with cardiovascular disease, diabetes, and hypertension also suffer more severe symptoms from COVID-19. Although hypertension is associated with an increased risk of severe COVID-19 and higher mortality rate in these patients, few studies have looked into the impact of COVID-19 on the likelihood of developing hypertension. This retrospective study will attempt to answer whether COVID-19 is associated with higher incidence of new-onset hypertension. If so, we will also attempt to investigate whether the severity of COVID-19 (hospitalized or not) will affect the rate of hypertensive development. This study will be performed using SQLite database for data queries and SPSS for statistical analyses. COVID-19 and non-COVID-19 patients (all without hypertension) admitted to Montefiore hospital systems between March 2020 and October 2021 will be screened, and blood pressure at the time of admission and after one month will be analyzed. New-onset hypertension will be identified according to the Eight Joint National Committee and European Society of Cardiology Guidelines, and the correlation between new-onset hypertension and COVID-19 status will be compared with paired sample t-tests (p-value less than 0.05 will be considered significant). If a significant correlation is found, we will also analyze and compare two groups of COVID-19 patients for the rate of new-onset hypertension: one group hospitalized because of COVID-19, and one not hospitalized. Systolic and diastolic blood pressure data will again be analyzed after one month. The hypothesis for the experiment is that both the status of COVID-19-positive and the severity of Covid will increase the rate of hypertension in individuals. If COVID-19 is shown to be a risk factor of developing or accelerating hypertension, hypertension-vulnerable individuals should get additional treatment or therapy to avoid the development of hypertension after contracting COVID-19.